FY2025 Earnings Estimate for Amarin Issued By Zacks Research

Amarin Co. plc (NASDAQ:AMRN) – Stock analysts at Zacks Research lowered their FY2025 earnings per share estimates for shares of Amarin in a report released on Tuesday, February 11th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.34) per share for the year, down from their previous forecast of ($0.33). The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.10) EPS.

Separately, StockNews.com raised Amarin from a “sell” rating to a “hold” rating in a research report on Tuesday.

Amarin Stock Up 8.1 %

Shares of AMRN stock opened at $0.61 on Friday. Amarin has a fifty-two week low of $0.43 and a fifty-two week high of $1.36. The stock’s 50-day moving average is $0.52 and its two-hundred day moving average is $0.57.

Institutional Trading of Amarin

Several large investors have recently made changes to their positions in the stock. Waterfront Wealth Inc. boosted its stake in shares of Amarin by 181.4% during the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company’s stock worth $1,204,000 after acquiring an additional 1,599,956 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock worth $816,000 after acquiring an additional 104,939 shares in the last quarter. Quinn Opportunity Partners LLC boosted its stake in shares of Amarin by 85.2% during the 4th quarter. Quinn Opportunity Partners LLC now owns 1,106,539 shares of the biopharmaceutical company’s stock worth $537,000 after acquiring an additional 508,989 shares in the last quarter. LCM Capital Management Inc boosted its stake in shares of Amarin by 3.1% during the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 25,100 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Amarin during the 4th quarter worth about $343,000. Institutional investors own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.